Utrophin

From WikiMD's WELLNESSPEDIA

Utrophin is a protein that in humans is encoded by the UTRN gene. Utrophin is a large, cytoskeletal protein that is homologous to dystrophin, the protein mutated in patients with Duchenne Muscular Dystrophy (DMD). Due to its structural and functional similarities to dystrophin, utrophin has been studied extensively as a potential therapeutic target for DMD.

Structure[edit]

Utrophin is a member of the spectrin superfamily of proteins, which are known for their role in maintaining cell structure and integrity. It shares a similar domain structure with dystrophin, including a C-terminal domain that interacts with the dystroglycan complex, a central rod domain composed of spectrin-like repeats, and an N-terminal actin-binding domain. This structural similarity suggests that utrophin can compensate for the lack of dystrophin in muscle cells, potentially ameliorating the muscle weakness and degeneration seen in DMD.

Function[edit]

The primary function of utrophin is to stabilize the muscle cell membrane (sarcolemma) during muscle contraction and relaxation cycles. It achieves this by linking the actin cytoskeleton of muscle fibers to the extracellular matrix through the dystroglycan complex. This linkage is crucial for the integrity of muscle fibers and for the transmission of force generated within muscle cells to the bones, leading to movement.

Clinical Significance[edit]

Utrophin's similarity to dystrophin makes it a promising candidate for gene therapy and other therapeutic strategies in the treatment of DMD. Upregulation of utrophin expression in muscle cells has been proposed as a strategy to compensate for the lack of functional dystrophin in DMD patients. Several approaches, including pharmacological upregulation and gene therapy, are being explored to increase utrophin levels in dystrophic muscles.

Research and Development[edit]

Research into utrophin modulation as a therapeutic approach for DMD has led to the development of small molecules that can upregulate utrophin expression. These molecules aim to provide a functional substitute for dystrophin, thereby mitigating the progression of muscle degeneration in DMD patients. Clinical trials are ongoing to evaluate the efficacy and safety of these utrophin modulators.

See Also[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.